Paris and London, November 29 (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for KOMBOGLYZETM (saxagliptin and metformin HCl immediate-release fixed dose combination) that will cover the 27 Member States of the European Union. The indication for KOMBOGLYZE is as an adjunct to diet and exercise [...]
Tag Archive > Treatment Of Type 2 Diabetes
KOMBOGLYZE? (saxagliptin and metformin HCl Immediate-Release) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca today announced that the Marketing Authorisation Application for KOMBOGLYZE(TM) (saxagliptin and metformin HCl immediate-release fixed dose combination) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), as an adjunct to diet and exercise, for the treatment of type 2 diabetes [...]
Study Finds That ONGLYZA(TM) (saxagliptin) When Added to Metformin was Non-Inferior to JANUVIA (sitagliptin) When Added to Metformin in Reducing Hemoglobin (HbA1c) in Adults With Type 2 Diabetes Mellitus
Princeton, New Jersey and London (ots/PRNewswire) – Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA(TM) (saxagliptin) 5 mg per day achieved the primary objective of demonstrating non-inferiority compared to the addition of treatment with [...]
Onglyza(R) (saxagliptin) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabetes
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) (LSE: AZN) announced today that the European Commission has granted marketing authorisation for Onglyza in the 27 countries of the European Union. Onglyza is indicated as a once-daily 5 mg oral tablet dose in adult patients with type 2 diabetes mellitus [...]
ONGLYZA(TM) (saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (LSE: AZN) today announced that their marketing authorisation application for ONGLYZA(TM) (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or [...]
New NICE Guideline for Type 2 Diabetes Recognises Benefits From Newer Agents for Blood Glucose Control
London (ots/PRNewswire) – – For Healthcare and Pharmaceutical Correspondents Only – NICE Recommends Considering DPP-4 Inhibitors as a Second Line Treatment Option in Appropriate Patients Merck Sharp & Dohme Limited (MSD) welcomes the publication of the guideline for type 2 diabetes newer agents1 from the National Institute for Health and Clinical Excellence (NICE) in the [...]
